Healios to fast-track pluripotent stem cell therapy

Latest articles

Cellino bags $80 million to autonomise stem cell therapy manufacturing

Leaps by Bayer leads $80m Series A to enable Cellino to significantly expand patient access to stem cell-based therapies. Cellino Biotech, Inc, an autonomous stem cell...

“World’s first” cultural-matching app for care sector launches

Care receivers can be paired with carer based on religious understanding and culture thanks to AI tech developed during pandemic. A graduate has created what...

Biotech LyGenesis expands its liver regeneration tech

A new peer-reviewed paper demonstrates the success of using fat-associated lymphoid clusters as expandable niches for ectopic liver regeneration. LyGenesis, a clinical-stage biotech developing cell...

NURO embarks on funding round for neurotech communication system

World’s first multimodal neurotech operating system from NURO allows you to communicate using just your brain. DISCLOSURE: Longevity.Technology (a brand of First Longevity Limited) has...

Most read

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Editor's picks

Cellino bags $80 million to autonomise stem cell therapy manufacturing

Leaps by Bayer leads $80m Series A to enable Cellino to significantly expand patient access to stem cell-based therapies. Cellino Biotech, Inc, an autonomous stem cell...

“World’s first” cultural-matching app for care sector launches

Care receivers can be paired with carer based on religious understanding and culture thanks to AI tech developed during pandemic. A graduate has created what...

Biotech LyGenesis expands its liver regeneration tech

A new peer-reviewed paper demonstrates the success of using fat-associated lymphoid clusters as expandable niches for ectopic liver regeneration. LyGenesis, a clinical-stage biotech developing cell...

Click the globe for translations.

Healios K.K. to bring its novel regenerative pluripotent stem cell treatments to market through accelerated Japanese approvals process.

Stem cell pioneers Healios KK will use the upcoming JP Morgan Healthcare Conference and Biotech Showcase in San Francisco CA to highlight its innovative approach to regenerative medication.

The company, which is Japan’s leading clinical stage biotech company, is focused on harnessing the power of stem cells for regenerative therapies which include organ regeneration [1].

Longevity.Technology: Healios is using cutting edge stem cell technology to address a range of serious conditions. Time is of the essence and they clearly believe that getting these treatments to market as quickly as possible has the potential to accelerate commercialisation.

The company’s CFO Richard Kincaid will use the biotech conference, being held between the 13th and 16th January, to present the company’s strategy in regenerative medicine. The therapy combines near-term and potentially accelerated commercialisation of Somatic Stem Cell (SSC) based treatments with the development of next generation therapies thanks to its induced Pluripotent Stem Cell technology platform.

Healios is currently in a pivotal second/third stage trial in Japan in Ischemia stroke which offers the potential for effective treatment.

In addition, it is also in the middle of a Phase 2 trial in acute respiratory distress syndrome (ARDS) in Japan and hopes to deliver the world’s first approved therapeutic drug.

Assuming these studies are completed successfully, Healios intends to accelerate along the path to approval and commercialisation thanks to Japan’s highly favourable regulatory framework, the Conditional and Time Limited Authorisation System, or SAKIGAKE in Japanese [2].

The strategy was conceived by the ministry of health to accelerate the development of innovative medicines and, where possible, accelerate the practical application of off label life saving medications to the wider audience.

Alongside this, Healios is developing a proprietary gene modified iPSC Platform of non-immunogenic, off-the-shelf (allogenic) ‘Universal Donor Cells’ for applications in next-generation therapies in ophthalmology, organ regeneration, and immuno-oncology.

This includes the development of iPSC derived gene-modified natural killer cells, which can offer long-lasting effects while still avoiding the need for immunosuppressive drug treatment.

[1] https://prn.to/35yAQ1e

[2] https://bit.ly/39UAcym

Image credit: Healios

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

Most popular

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Sugar-proof your health with the GLYLO weight loss and antiaging supplement

Move your New Year's resolution up a gear with GLYLO, a double-action supplement that can increase weight loss while also slowing aging. Choosing an effective...

Related articles

Cellino bags $80 million to autonomise stem cell therapy manufacturing

Leaps by Bayer leads $80m Series A to enable Cellino to significantly expand patient access to stem cell-based therapies. Cellino Biotech, Inc, an autonomous stem cell...

Biotech LyGenesis expands its liver regeneration tech

A new peer-reviewed paper demonstrates the success of using fat-associated lymphoid clusters as expandable niches for ectopic liver regeneration. LyGenesis, a clinical-stage biotech developing cell...

Exercise protects brain against Alzheimer’s by safeguarding synapses

UCSF researchers find enhanced nerve transmission is seen in older adults who remain active. When elderly people stay active, their brains have more of a...

Mental illness drug discovery company Neurai Life Sciences launches

AI will drive discovery of innovative small molecules and next generation therapies to treat mental health disorders. Wuhan, a bioceutical company focused on alternative plant-based...

StarkAge secures 2 million euros for senescence targeting therapy

Funding from Bpifrance's Deeptech program will drive development of company’s immunotherapy approach targeting cellular senescence in age-related disease. French biotech startup StarkAge Therapeutics today announced...

    Subscribe to our newsletter